Tubulointerstitial nephritis is an important
cause of acute kidney failure and chronic kidney disease. This entity is
characterized by an infiltration of inflammatory cells in the renal
interstitial area. Renal biopsy remains as the gold standard to diagnose this
entity in where probable cause can be guided with the type of inflammatory
cells involved. There are many causes of tubulointerstitial nephritis described
such as secondary to infections, drug-induced, autoimmune disorders,
obstructive uropathy, heavy metal-induced, hereditary disorders, neoplasm and
idiopathic.
Neoplastic causes are the rarest etiology of
tubulointerstitial nephritis, and within these, lymphomas are even not common.
Generally, neoplasms infiltrate renal parenchyma from tumor cells surrounding
it and its affectation is secondary. There are few cases reported of primary source,
specifically primary renal lymphomas, with no more than 70 cases reported in
the literature and the majority are of non-Hodgkin lymphoma. Its development is
not elucidated yet, because the kidney does not have naturally lymphocytes
inside it. The proposed pathogenesis implicated in its origin is the lymphatic
renal parenchyma, or it can be because of any chronic inflammatory process that
cause cellular changes in lymphocytes and predispose to neoplasms.
The most common initial clinical presentation can
be since asymptomatic presentation or with weight loss, fever, and flank pain.
Laboratory studies report hematuria, leukocyturia and sub-nephrotic proteinuria
range.
Computed tomography is the most sensitive image
for evaluation ok kidneys in patients with suspected renal lymphoma. The forms
of presentation detected by computed tomography are multiple masses, solitary
masses, contiguous retroperitoneal or perirenal extension and infiltrative
disease. Infiltrative presentation encompasses 20% of the forms of presentation,
affects bilaterally with enlargement of the kidney. Contrast images are needed to
demonstrate poorly defined interface with the normal renal parenchyma, a characteristic
of focal areas of infiltrative disease.
The prognosis reported is poor, and the median
survival is less than a year. The management include chemotherapy with scheme
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and
in some cases, nephrectomy is recommended. Results of this management are only described
in case report or case series.
In our case patient, she is receiving chemotherapy and intermitent hemodyalisis, and also continuosly evaluated by nephrology and oncology team.